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did appear to differ. Nevertheless, we believe that our reported
findings are relevant to U.S. blacks given the same rank-order of
BP responses within each group as well as the fact that the majority
of black participants were from the U.S.
We agree with Drs. Humma and Adenekan that dietary sodium
intake and body size may potentially confound BP changes to
pharmacological agents. We (1) and others (2,3) have shown that
higher levels of dietary sodium intake attenuates the BP lowering
effect of antihypertensive agents, especially drugs working primar-
ily on the renin-angiotensin-aldosterone-kinin system. The study
participants in our trial were not counseled to restrict dietary
sodium intake nor was urinary sodium excretion measured. Thus,
the effect of dietary sodium by region, ethnic group, or drug
treatment cannot be determined. Conversely, it is plausible that
high levels of dietary sodium may have attenuated the BP lowering
effect of losartan moreso than eplerenone.
We also agree that body size can influence BP change to
pharmacological interventions. In fact, this is an underrecognized
factor influencing treatment responses (4,5). The body weights
(weighted for the proportions of men and women) in the losartan
and eplerenone groups, respectively, were 91.9 kg and 88.7 kg,
which corresponds to a difference of 3.2 kg. When BMI levels are
compared, no difference existed between the eplerenone and
losartan groups in men and only a very small difference in women.
Median BMI levels in women randomized to eplerenone and
losartan, respectively, were 32.1 and 33.8 kg/m2; in men, median
BMI rates for the same two groups were 29.7 and 29.6 kg/m2,
respectively. We do not believe that these very slight differences in
body size account for the BP response differences between
eplerenone and losartan that we reported.
In conclusion, the questions raised are certainly important.
However, we do not believe the relatively modest body size
differences, as determined by any metric, explains our results to any
significant degree. Finally, assuming that high levels of dietary
sodium intake importantly influenced BP responses, our data
suggest that eplerenone lowers BP more robustly in American and
South African blacks than does losartan in high-sodium-
consuming hypertensives.
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Neopterin—A Forgotten Biomarker
In a recent issue of the Journal, Blake and Ridker (1) summarized
findings regarding the prognostic role of C-reactive protein (CRP)
and other inflammatory markers in patients with acute coronary
syndromes (ACS). We would like to point out that the investiga-
tors did not include the role of neopterin in this context. Neopterin
(2), a pteridine derivative and a by-product of the guanosine
triphosphate–biopterin pathway (3), is produced by activated
macrophages and represents a marker of immune activation.
Studies from our group (4) and others (5,6) have shown that
circulating neopterin levels are higher in patients with ACS
compared to patients with a history of myocardial infarction,
patients with stable angina pectoris, or control subjects. High
neopterin levels may be a marker of coronary disease activity, as
suggested by its association with angiographically complex lesions
in patients with unstable angina (7) and its role as a marker of
future cardiovascular events in women with coronary artery disease
(CAD) (8). The prognostic significance of neopterin in ACS
patients has been reported by Auer et al. (9), albeit in a small group
of patients. Preliminary prospective work from our unit has
recently shown that, in patients with CAD, serum neopterin is an
independent predictor of major adverse coronary events at one-
year follow-up (data not published).
Finally, although convincing evidence exists regarding the
prognostic value of inflammatory markers in patients with ACS,
the independent and/or complementary role of different biomar-
kers has not been systematically investigated in large prospective
studies. The ongoing SIESTA (Systemic Inflammation Evaluation
in patients with non–ST-segment elevation Acute coronary syn-
dromes) study (10)—a prospective multicenter trial designed to
assess the relative prognostic role of diverse markers of inflamma-
tion, including, among many others, CRP, neopterin, cell adhesion
molecules, and pregnancy-associated plasma protein A—will help
to elucidate the issue.
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Transient Left Ventricular Apical
Ballooning and Outflow Tract Obstruction
In the interesting syndrome of transient left ventricular apical
ballooning (TLVAB) without coronary artery stenosis mimicking
acute myocardial infarction, originally described by Tsuchihashi et
al. (1), clinical manifestations in most patients were preceded by
severe physical or emotional stress, suggesting a catecholamine-
mediated mechanism. In a recent issue of the Journal, Abe et al. (2)
described the clinical characteristics of a new series of 17 patients
with TLVAB and disscuss and investigate different possible
pathogenic mechanisms for this syndrome. The investigators could
not identify any specific cause, suggesting neurogenic myocardial
stunning induced by emotional or physical stress as the most
probable etiology. Surprisingly, the previously suggested (1) pos-
sible role of a transient dynamic left ventricular outflow tract
(LVOT) obstruction in the pathogenesis of this syndrome was not
investigated by these researchers, who did not even mention the
possible existence of such gradients in their patients. However, we
believe there is much evidence indicating that this relation actually
exist. In fact, a transient dynamic LVOT gradient was detected at
initial evaluation in a substantial proportion of the patients
described by Tsuchihashi et al. (1), and in other cases of this
syndrome described elsewhere (3,4). In these patients, the clinical
and hemodynamic situation improved as the gradient disappeared.
Moreover, in some of the patients presenting with cardiogenic
shock, this situation persisted until the dynamic obstruction was
diagnosed and specifically treated (3).
Thus, at least in some patients, a possible mechanism for
TLVAB could be a dynamic LVOT obstruction preceding the
ischemic event. Once present, the dynamic obstruction elevates left
ventricular filling pressures, increasing myocardial oxygen demand
at the mid-to-apical cavity. If this situation persists, apical hypo-
perfusion and ischemia may result, with eventual apical infarc-
tion. In fact, it is well known that, even in normal hearts,
exposure to an exogenous catecholamine, such as dobutamine
infusion, can precipitate dynamic LVOT obstruction (5). Some
patients, primarily women, may have geometric predisposition
(sigmoid interventricular septum, small LVOT, reduced left
ventricular volume) to dynamic LVOT obstruction, which may
manifest only in the setting of intense adrenergic stimulation or
hypovolemia (3,5). In these susceptible patients, increased
adrenergic tone might produce primary LVOT obstruction
leading to secondary ischemia and focal wall-motion abnormal-
ities. Thus, the intense physical or emotional stress that
precedes apical ischemia in most patients with TLVAB could be
the trigger for the acute development of LVOT obstruction
capable of producing severe apical ischemia.
Identification of acute dynamic LVOT obstruction as the
possible initial mechanism in some of these patients may have
important clinical and therapeutic implications, as the use of
traditional measures to treat patients with chest pain and
evidence of myocardial ischemia, including nitrates and after-
load reduction, would actually increase the LVOT gradient,
causing further clinical deterioration, while abolishing the
gradient (with beta-blockers, intravenous fluids, or alpha-
adrenergic receptor stimulation) might be beneficial and even
life-saving (3). Moreover, treatment for secondary prevention
would depend also on the suspected underlying mechanism.
Eventually, in those patients in whom an acute dynamic LVOT
obstruction mechanism is suspected, the possibility of perform-
ing tests of provocation, such as dobutamine stress echocardi-
ography, should be considered.
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